CVE-2023-23918A privilege escalation vulnerability exists in Node.js <19.6.1, <18.14.1, <16.19.1 and <14.21.3 that made it possible to bypass the experimental Permissions (https://nodejs.org/api/permissions.html)…
Updated under an hour ago ()
Does this affect you?
It affects nodejs node.js. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
A privilege escalation vulnerability exists in Node.js <19.6.1, <18.14.1, <16.19.1 and <14.21.3 that made it possible to bypass the experimental Permissions (https://nodejs.org/api/permissions.html) feature in Node.js and access non authorized modules by using process.mainModule.require(). This only affects users who had enabled the experimental permissions option with --experimental-policy.
- CVSS
- 7.5 HIGH (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
- Weakness (CWE)
- CWE-863
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Modified
- Record last updated
- Oct 24, 2026
- First seen by InfoSec Signals
- Oct 24, 2026
Affected products
nodejs node.js nodejs:node.js | from 14.0.0 through 14.14.0; from 14.0.0 before 14.21.3; from 16.0.0 through 16.12.0; from 16.0.0 before 16.19.1; from 18.0.0 through 18.11.0; from 18.0.0 before 18.14.1; from 19.0.0 before 19.6.1 | NVD |
References
- https://nodejs.org/en/blog/vulnerability/february-2023-security-releases/patch, vendor-advisory
- https://security.netapp.com/advisory/ntap-20230316-0008/
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.